<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007222318
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SETAPRO 10 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESCITALOPRAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        46.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Setapro&trade; contains the active substance escitalopram. Setapro&trade; belongs to<br />a group of antidepressants called selective serotonin reuptake inhibitors (SSRIs).<br />These medicines act on the serotonin-system in the brain by increasing the serotonin<br />level. Disturbances in the serotonin-system are considered an important factor in the<br />development of depression and related diseases.<br />Setapro&trade; contains escitalopram and is used to treat depression (major depressive<br />episodes) and anxiety disorders (such as panic disorder with or without agoraphobia,<br />social anxiety disorder, generalised anxiety disorder and obsessive-compulsive<br />disorder).<br />It may take a couple of weeks before you start to feel better. Continue to take Setapro<br />&trade;, even if it takes some time before you feel any improvement in your condition.<br />You must talk to a doctor if you do not feel better or if you feel worse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Setapro&trade;<br />&bull; If you are allergic to escitalopram or any of the other ingredients of this medicine<br />(listed in section 6).<br />&bull; If you take other medicines which belong to a group called MAO inhibitors,<br />including selegiline (used in the treatment of Parkinson&rsquo;s disease), moclobemide<br />(used in the treatment of depression) and linezolid (an antibiotic).<br />&bull; If you are born with or have had an episode of abnormal heart rhythm (seen at<br />ECG; an examination to evaluate how the heart is functioning).<br />&bull; If you take medicines for heart rhythm problems or that may affect the heart&rsquo;s<br />rhythm (see section 2 &ldquo;Other medicines and Setapro&trade;&rdquo;).<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Setapro&trade;. Please tell your doctor if<br />you have any other condition or illness, as your doctor may need to take this into<br />consideration. In particular, tell your doctor:<br />&bull; If you have epilepsy. Treatment with Setapro&trade; should be stopped if seizures occur<br />for the first time, or if there is an increase in the seizure frequency (see also section 4<br />&ldquo;Possible side effects&rdquo;).<br />&bull; If you suffer from impaired liver or kidney function. Your doctor may need to adjust<br />your dosage.<br />&bull; If you have diabetes. Treatment with Setapro&trade; may alter glycaemic control. Insulin<br />and/or oral hypoglycaemic dosage may need to be adjusted.<br />&bull; If you have a decreased level of sodium in the blood.<br />&bull; If you have a tendency to easily develop bleedings or bruises.<br />&bull; If you are receiving electroconvulsive treatment.<br />&bull; If you have coronary heart disease.<br />&bull; If you suffer or have suffered from heart problems or have recently had a heart<br />attack.<br />&bull; If you have a low resting heart-rate and/or you know that you may have salt<br />depletion as a result of prolonged severe diarrhoea and vomiting (being sick) or<br />usage of diuretics (water tablets).<br />&bull; If you experience a fast or irregular heart beat, fainting, collapse or dizziness on<br />standing up, which may indicate abnormal functioning of the heart rate.<br />&bull; If you have or have previously had eye problems, such as certain kinds of glaucoma<br />(increased pressure in the eye).<br />Please note<br />Some patients with manic-depressive illness may enter into a manic phase. This is<br />characterized by unusual and rapidly changing ideas, inappropriate happiness and<br />excessive physical activity. If you experience this, contact your doctor.<br />Symptoms such as restlessness or difficulty in sitting or standing still can also occur<br />during the first weeks of the treatment. Tell your doctor immediately if you<br />experience these symptoms.<br />Thoughts of suicide and worsening of your depression or anxiety disorder<br />If you are depressed and/or have anxiety disorders you can sometimes have thoughts<br />of harming or killing yourself. These may be increased when first starting<br />antidepressants, since these medicines all take time to work, usually about two weeks<br />but sometimes longer.<br />You may be more likely to think like this:<br />&bull; If you have previously had thoughts about killing or harming yourself.<br />&bull; If you are a young adult. Information from clinical trials has shown an increased<br />risk of suicidal behaviour in adults aged less than 25 years with psychiatric<br />conditions who were treated with an antidepressant.<br />If you have thoughts of harming or killing yourself at any time, contact your doctor<br />or go to a hospital straight away.<br />You may find it helpful to tell a relative or close friend that you are depressed or<br />have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell<br />you if they think your depression or anxiety is getting worse, or if they are worried<br />about changes in your behaviour.<br />Children and adolescents under 18 years of age<br />Setapro&trade; should normally not be used for children and adolescents under 18 years.<br />Also, you should know that patients under 18 have an increased risk of side effects<br />such as suicide attempts, suicidal thoughts and hostility (predominately aggression,<br />oppositional behaviour and anger) when they take this class of medicines. Despite<br />this, your doctor may prescribe Setapro&trade; for patients under 18 because he/she<br />decides that this is in their best interest. If your doctor has prescribed Setapro&trade; for a<br />patient under 18 and you want to discuss this, please go back to your doctor. You<br />should inform your doctor if any symptoms listed above develop or worsen when<br />patients under 18 are taking Setapro&trade;. Also, the long term safety effects concerning<br />growth, maturation and cognitive and behavioural development of Setapro&trade; in this<br />age group have not yet been demonstrated.<br />Other medicines and Setapro&trade;<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take<br />any other medicines.<br />Tell your doctor if you are taking any of the following medicines:<br />&bull; &ldquo;Non-selective monoamine oxidase inhibitors (MAOIs)&rdquo;, containing phenelzine,<br />iproniazid, isocarboxazid, nialamide, and tranylcypromine as active ingredients. If<br />you have taken any of these medicines you will need to wait 14 days before you start<br />taking Setapro&trade;. After stopping Setapro&trade; you must allow 7 days before taking any<br />of these medicines.<br />&bull; &ldquo;Reversible, selective MAO-A inhibitors&rdquo;, containing moclobemide (used to treat<br />depression).<br />&bull; &ldquo;Irreversible MAO-B inhibitors&rdquo;, containing selegiline (used to treat Parkinson&rsquo;s<br />disease). These increase the risk of side effects.<br />&bull; The antibiotic linezolid.<br />&bull; Lithium (used in the treatment of manic-depressive disorder) and tryptophan.<br />&bull; Imipramine and desipramine (both used to treat depression).<br />&bull; Sumatriptan and similar medicines (used to treat migraine) and tramadol (used<br />against severe pain). These increase the risk of side effects.<br />&bull; Cimetidine, lansoprazole and omeprazole (used to treat stomach ulcers),<br />fluvoxamine (antidepressant) and ticlopidine (used to reduce the risk of stroke).<br />These may cause increased blood levels of escitalopram.<br />&bull; St. John&#39;s wort hypericum perforatum) - a herbal remedy used for depression.</p><p>&bull; Acetylsalicylic acid (aspirin) and non-steroidal anti-inflammatory drugs (medicines<br />used for pain relief or to thin the blood, so called antiplatelet)</p><p>These may increase<br />bleeding-tendency.<br />&bull; Warfarin, dipyridamole, and phenprocoumon (medicines used to thin the blood, so<br />called anti-coagulant). Your doctor will probably check the coagulation time of your<br />blood when starting and discontinuing Setapro&trade; in order to verify that your dose of<br />anti-coagulant is still adequate.<br />&bull; Mefloquine (used to treat Malaria), bupropion (used to treat depression) and<br />tramadol (used to treat severe pain) due to a possible risk of a lowered threshold for<br />seizures.<br />&bull; Neuroleptics (medicines to treat schizophrenia, psychosis) and antidepressants<br />(tricyclic antidepressants and SSRIs) due to a possible risk of a lowered threshold for<br />seizures.<br />&bull; Flecainide, propafenone, and metoprolol (used in cardiovascular diseases)<br />clomipramine, and nortriptyline (antidepressants) and risperidone, thioridazine, and<br />haloperidol (antipsychotics). The dosage of Setapro&trade; may need to be adjusted.<br />&bull; Medicines that decrease blood levels of potassium or magnesium, as these<br />conditions increase the risk of life-threatening heart rhythm disorders.<br />Do not take Setapro&trade; if you take medicines for heart rhythm problems or medicines<br />that may affect the heart&rsquo;s rhythm, such as Class IA and III antiarrhythmics,<br />antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol), tricyclic<br />antidepressants, certain antimicrobial agents (e.g. sparfloxacin, moxifloxacin,<br />erythromycin IV, pentamidine, anti-malarial treatment particularly halofantrine),<br />certain antihistamines (e.g. astemizole, mizolastine). If you have any further<br />questions about this you should speak to your doctor.<br />Setapro&trade; with food, drink and alcohol<br />Setapro&trade; can be taken with or without food (see section 3 &ldquo;How to take<br />Setapro&trade;&rdquo;).<br />As with many medicines, combining Setapro&trade; with alcohol is not advisable,<br />although Setapro&trade; is not expected to interact with alcohol.<br />Pregnancy, breast-feeding and fertility<br />Inform your doctor if you are pregnant or planning to become pregnant. Do not take<br />Setapro&trade; if you are pregnant or breast-feeding, unless you and your doctor have<br />discussed the risks and benefits involved.<br />If you take Setapro&trade; during the last 3 months of your pregnancy you should be<br />aware that the following effects may be seen in your newborn baby: trouble with<br />breathing, bluish skin, fits, body temperature changes, feeding difficulties, vomiting,<br />low blood sugar, stiff or floppy muscles, vivid reflexes, tremor, jitteriness, irritability,<br />lethargy, constant crying, sleepiness and sleeping difficulties. If your newborn baby<br />has any of these symptoms, please contact your doctor immediately.<br />Make sure your doctor knows you are on Setapro&trade;. When taken during pregnancy,<br />particularly in the last 3 months of pregnancy, medicines like<br />Setapro&trade; may increase the risk of a serious condition in babies, called persistent<br />pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and<br />appear bluish. These symptoms usually begin during the first 24 hours after the baby<br />is born. If this happens to your baby you should contact your doctor immediately.<br />If used during pregnancy Setapro&trade; should never be stopped abruptly. It is expected<br />that Setapro&trade; will be excreted into breast milk. Citalopram, a medicine like<br />escitalopram, has been shown to reduce the quality of sperm in animal studies.<br />Theoretically, this could affect fertility, but impact on human fertility has not been<br />observed as yet.<br />Driving and using machines<br />You are advised not to drive a car or operate machinery until you know how<br />Setapro&trade; affects you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your<br />doctor or pharmacist if you are not sure.<br />Adults<br />Depression:<br />The normally recommended dose of Setapro&trade; is 10 mg taken as one daily dose. The<br />dose may be increased by your doctor to a maximum of 20 mg per day.<br />Panic disorder:<br />The starting dose of Setapro&trade; is 5 mg as one daily dose for the first week before<br />increasing the dose to 10 mg per day. The dose may be further increased by your<br />doctor to a maximum of 20 mg per day.<br />Social anxiety disorder:<br />The normally recommended dose of Setapro&trade; is 10 mg taken as one daily dose.<br />Your doctor can either decrease your dose to 5 mg per day or increase the dose to a<br />maximum of 20 mg per day, depending on how you respond to the medicine.</p><p>Generalised anxiety disorder:<br />The normally recommended dose of Setapro&trade; is 10 mg taken as one daily dose. The<br />dose may be increased by your doctor to a maximum of 20 mg per day.<br />Obsessive-compulsive disorder:<br />The normally recommended dose of Setapro&trade; is 10 mg taken as one daily dose. The<br />dose may be increased by your doctor to a maximum of 20 mg per day.<br />Elderly patients (above 65 years of age)<br />The recommended starting dose of Setapro&trade; is 5 mg taken as one daily dose. The<br />dose may be increased by your doctor to 10 mg per day.<br />Children and adolescents (below 18 years of age)<br />Setapro&trade; should not normally be given to children and adolescents. For further<br />information please see section 2 &ldquo;Before you take Setapro&trade;&rdquo;.<br />You can take Setapro&trade; with or without food. Swallow the tablet with some water. Do<br />not chew them, as the taste is bitter.<br />If necessary, you can divide the tablets by firstly placing the tablet on a flat surface<br />with the score facing upwards. The tablets may then be broken by pressing down on<br />each end of the tablet, using both forefingers.<br />Duration of treatment<br />It may take a couple of weeks before you start to feel better. Continue to take<br />Setapro&trade; even if it takes some time before you feel any improvement in your<br />condition.<br />Do not change the dose of your medicine without talking to your doctor first.<br />Continue to take Setapro&trade; for as long as your doctor recommends. If you stop your<br />treatment too soon, your symptoms may return. It is recommended that treatment<br />should be continued for at least 6 months after you feel well again.<br />If you take more Setapro&trade; than you should<br />If you take more than the prescribed dose of Setapro&trade;, contact your doctor or nearest<br />hospital emergency department immediately. Do this even if there are no signs of<br />discomfort. Some of the signs of an overdose could be dizziness, tremor, agitation,<br />convulsion, coma, nausea, vomiting, change in heart rhythm, decreased blood<br />pressure and change in body fluid/salt balance. Take the Setapro&trade; box/container with<br />you when you go to the doctor or hospital.<br />If you forget to take Setapro&trade;<br />Do not take a double dose to make up for forgotten doses. If you do forget to take<br />a dose, and you remember before you go to bed, take it straight away. Carry on as<br />usual the next day. If you only remember during the night, or the next day, leave out<br />the missed dose and carry on as usual.<br />If you stop taking Setapro&trade;<br />Do not stop taking Setapro&trade; until your doctor tells you to do so. When you have<br />completed your course of treatment, it is generally advised that the dose of<br />Setapro&trade; is gradually reduced over a number of weeks.<br />When you stop taking Setapro&trade;, especially if it is abruptly, you may feel<br />discontinuation symptoms. These are common when treatment with Setapro&trade; is<br />stopped. The risk is higher, when Setapro&trade; has been used for a long time or in high<br />doses or when the dose is reduced too quickly. Most people find that the symptoms<br />are mild and go away on their own within two weeks. However, in some patients they<br />may be severe in intensity or they may be prolonged (2-3 months or more). If you get<br />severe discontinuation symptoms when you stop taking Setapro&trade;, please contact<br />your doctor. He or she may ask you to start taking your tablets again and come off<br />them more slowly.<br />Discontinuation symptoms include: Feeling dizzy (unsteady or off-balance), feelings<br />like pins and needles, burning sensations and (less commonly) electric shock<br />sensations, including in the head, sleep disturbances (vivid dreams, nightmares,<br />inability to sleep), feeling anxious, headaches, feeling sick (nausea), sweating<br />(including night sweats), feeling restless or agitated, tremor (shakiness), feeling<br />confused or disorientated, feeling emotional or irritable, diarrhoea (loose stools),<br />visual disturbances, fluttering or pounding heartbeat (palpitations).<br />If you have any further questions on the use of this product, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets<br />them.<br />The side effects usually disappear after a few weeks of treatment. Please be aware<br />that many of the effects may also be symptoms of your illness and therefore will<br />improve when you start to get better.<br />If you experience any of the following symptoms you should contact your doctor<br />or go to the hospital straight away:<br />Uncommon (may affect up to 1 in 100 people):<br />&bull; Unusual bleeds, including gastrointestinal bleeds<br />Rare (may affect up to 1 in 1000 people):<br />&bull; Swelling of skin, tongue, lips, or face, or have difficulties breathing or swallowing<br />(allergic reaction).<br />&bull; High fever, agitation, confusion, trembling and abrupt contractions of muscles these<br />may be signs of a rare condition called serotonin syndrome.<br />Not known (frequency cannot be estimated from the available data):<br />&bull; Difficulties urinating<br />&bull; Seizures (fits), see also section 2 &ldquo;Warnings and precautions&rdquo;<br />&bull; Yellowing of the skin and the white in the eyes are signs of liver function<br />impairment/hepatitis<br />&bull; Fast, irregular heart beat, fainting which could be symptoms of a life-threatening<br />condition known as torsade de pointes<br />&bull; Thoughts of harming or killing yourself, see also section 2 &quot;Warnings and<br />precautions&quot;<br />In addition to the above, the following side effects have been reported:<br />Very common (may affect more than 1 in 10 people):<br />&bull; Feeling sick (nausea)<br />&bull; Headache<br />Common (may affect up to 1 in 10 people):<br />&bull; Blocked or runny nose (sinusitis)<br />&bull; Decreased or increased appetite<br />&bull; Anxiety, restlessness, abnormal dreams, difficulties falling asleep, feeling sleepy,<br />dizziness, yawning, tremors, prickling of the skin<br />&bull; Diarrhoea, constipation, vomiting, dry mouth<br />&bull; Increased sweating<br />&bull; Pain in muscle and joints (arthralgia and myalgia)<br />&bull; Sexual disturbances (delayed ejaculation, problems with erection, decreased sexual<br />drive and women may experience difficulties achieving orgasm)<br />&bull; Fatigue, fever<br />&bull; Increased weight<br />Uncommon (may affect up to 1 in 100 people):<br />&bull; Nettle rash (urticaria), rash, itching (pruritus)<br />&bull; Grinding one&rsquo;s teeth, agitation, nervousness, panic attack, confusion<br />&bull; Disturbed sleep, taste disturbance, fainting (syncope)<br />&bull; Enlarged pupils (mydriasis), visual disturbance, ringing in the ears (tinnitus)</p><p>&bull; Loss of hair<br />&bull; Excessive menstrual bleeding<br />&bull; Irregular menstrual period<br />&bull; Decreased weight<br />&bull; Fast heart beat<br />&bull; Swelling of the arms or legs<br />&bull; Nosebleeds<br />Rare (may affect up to 1 in 1000 people):<br />&bull; Aggression, depersonalisation, hallucination<br />&bull; Slow heart beat<br />Not known (frequency cannot be estimated from the available data):<br />&bull; Decreased levels of sodium in the blood (the symptoms are feeling: sick and unwell<br />with weak muscles; or confused)<br />&bull; Dizziness when you stand up due to low blood pressure (orthostatic hypotension)<br />&bull; Abnormal liver function test (increased amounts of liver enzymes in the blood)<br />&bull; Movement disorders (involuntary movements of the muscles)<br />&bull; Painful erections (priapism)<br />&bull; Signs of increased bleeding e.g. from skin and mucous membranes (ecchymosis)<br />&bull; Sudden swelling of skin or mucosa (angioedemas)<br />&bull; Increase in the amount of urine excreted (inappropriate ADH secretion)<br />&bull; Flow of milk in men and in women that are not nursing<br />&bull; Mania<br />&bull; An increased risk of bone fractures has been observed in patients taking this type of<br />medicine<br />&bull; Alteration of the heart rhythm (called &ldquo;prolongation of QT interval&rdquo;, seen on ECG,<br />measuring electrical activity of the heart).<br />In addition, a number of side effects are known to occur with drugs that work in a<br />similar way to escitalopram (the active ingredient of Setapro&trade;). These are:<br />&bull; Motor restlessness (akathisia)<br />&bull; Loss of appetite</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this<br />leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Do not store above 30 &deg;C.<br />&bull; Do not use this medicine after the expiry date stated on the blister and carton.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your<br />pharmacist how to throw away medicines you no longer use. These measures will<br />help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Setapro&trade; contains<br />The active substance is escitalopram.<br />&bull; Setapro&trade; Tablets 10 mg: Each film-coated tablet contains 10 mg Escitalopram (as<br />Oxalate).<br />&bull; Setapro&trade; Tablets 20 mg: Each film-coated tablet contains 20 mg Escitalopram (as<br />Oxalate).<br />The other ingredients are:<br />Core tablet content:<br />Microcrystalline cellulose , Talc, Colloidal silicon dioxide, Croscarmellose sodium<br />and Magnesium stearate.<br />Coating content:<br />Opadry white (which contains, Hypromellose, Titanium dioxide, Propylene glycol<br />and Talc).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                • Setapro™ 10mg Tablet: White to off white, oval, biconvex, film coated tablets,
engraved with ‘JP 119’ on one side and break line on other side.
• Setapro™ 20mg Tablet: White to off white, oval, biconvex, film coated tablets,
engraved with ‘JP 120’ on one side and break line on other side.
• Setapro™ 10mg Tablets available in a box of 30 film-coated tablets.
• Setapro™ 20mg Tablets available in a box of 30 film-coated tablets.
Not all packs may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co., Ltd., Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>۱. آثار جانبية خطيرة.</p><p>تحذير: الانتحار و الأدوية المضاة للإكتئاب<br />تزيد مضادات الاكتئاب مقارنة مع الدواء الوهمي من خطر التفكير في الانتحار والسلوك (الانتحارى)<br />في الأطفال والمراهقين وصغار البالغين و ذلك في الدراسات على المدى القصير للإضطراب الإكتئابي<br />والإضطرابات النفسية الأخرى. (MDD) الشديد<br />المراهقين، أو صغار البالغين موازنة هذا الخطر مع الحاجة لم تظهر الدراسات على المدى القصير زيادة في خطر الانتحار مع مضادات الاكتئاب مقارنة مع الدواء<br />الوهمي في البالغين بعد سن ۲٤ عاما. كان هناك انخفاض في الخطر مع مضادات الاكتئاب مقارنة مع<br />الدواء الوهمي في البالغين الذين أعمارهم ٦٥ و أكبر.<br />الإكتئاب وبعض الإضطرابات النفسية الأخرى هي في حد ذاتها مرتبطة بزيادة خطر الانتحار. يجب<br />مراقبة المرضى من جميع الأعمار الذين بدأوا العلاج بمضاد للإكتئاب بشكل مناسب، و ملاحظة تفاقم<br />الحالة السريرية عن كثب، السلوك الانتحاري أو التغيرات غير العادية في السلوك. ينبغي نصح الأسر<br />ومقدمي الرعاية للحاجة إلى مراقبة وثيقة والتواصل مع من وصف إس يتالوبرام لاستخدامه مع الأطفال المرضى أقل من ۱۲ سنة من العمر.<br />يجب على أي شخص يفكر في استخدام إس سيتالوبرام أو أي مضاد للإكتئاب آخر في الأطفال و<br />السريرية.<br />هذا الدواء. لم تتم الموافقة على إس يتالوبرام لاستخدامه مع الأطفال المرضى أقل من 12 سنة من العمر&nbsp;</p><p>&nbsp;</p><p>۲. ما هو سيتابرو وما هي إستخداماته.&nbsp;&nbsp;<br />يحتوي على المادة الفعالة إس سيتالوبرام. ينتمي إلى مجموعة من مضادات الإكتئاب تسمى &trade; سيتابرو<br />مثبطات امتصاص السيروتونين الانتقائية (اس اس اراي). هذه الأدوية تعمل على نظام السيروتونين في<br />الدماغ عن طريق زيادة مستوى السيروتونين. تعتبر الإضطرابات في جهاز السيروتونين عامل مهم في<br />تطور الإكتئاب والأمراض ذات الصلة.<br />يحتوي على المادة الفعالة إس سيتالوبرام و يستخدم لعلاج الإكتئاب (نوبات الإكتئاب الكبرى) و &trade; سيتابرو<br />إضطرابات القلق (مثل إضطراب الهلع مع أو بدون الخوف من رهاب الميادين، و إضطراب القلق<br />الإجتماعي، و إضطراب القلق العام واضطراب الوسواس القهري).<br />حتى لو استغرق ،&trade; قد يستغرق الأمر أسبوعين قبل أن تبدأ في الشعور بالتحسن. إستمر في تناول سيتابرو<br />ذلك بعض الوقت قبل أن تشعر بأي تحسن في حالتك.<br />يجب عليك التحدث مع الطبيب إذا كنت لا تشعر بتحسن أو إذا كنت تشعر بسوء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;موانع إستخدام سيتابرو<br />&bull; إذا كان لديك حساسية من إس سيتالوبرام أو أي من مكونات الدواء الأخرى ( المدرجة في<br />.( القسم ٦<br />بما ،(MAOIs) &bull; إذا كنت تتناول أدوية أخرى تنتمي إلى مجموعة تسمى مثبطات المونامينو أوكسيديز<br />في ذلك سيليجيلين (المستخدم في علاج مرض باركنسون)، مكلوبمايد (المستخدم في علاج الإكتئاب) و<br />لينزوليد (مضاد حيوي).<br />&bull; إذا كنت ولدت بضربات قلب غير طبيعية أو حدث معك واقعة من ضربات القلب غير الطبيعية<br />( شوهدت في تخطيط القلب ؛ وهوفحص لتقييم كيف يعمل القلب).<br />&bull; إذا كنت تتناول أدوية لمشاكل ضربات القلب أو أدوية قد تؤثر علي إيقاع القلب (انظر القسم ۲<br />سيتابرو .(&trade; الأخرى و الأدوية&quot;)<br />تحذيرات واحتياطات<br />يرجى إخبار الطبيب إذا كان لديك أي حالة أو أمراض .&trade; تحدث إلى طبيبك أو الصيدلي قبل تناول سيتابرو<br />أخرى، فطبيبك قد يحتاج إلى أخذ هذا بعين الاعتبار. على وجه الخصوص، أخبر طبيبك:<br />في حالة حدوث نوبات لأول مرة، أو إذا كان &trade; &bull; إذا كنت تعاني من الصرع. يجب إيقاف العلاج بسيتابرو<br />هناك زيادة في تردد النوبات (انظر أيضا القسم ٤ &quot;الآثار الجانبية المحتملة&quot;).<br />&bull; إذا كنت تعاني من ضعف وظائف الكبد أو الكلى. قد يحتاج طبيبك لتعديل جرعتك.<br />قد يغير السيطرة على السكر. قد تحتاج جرعة &trade; &bull; إذا كان لديك مرض السكري. العلاج بسيتابرو<br />الأنسولين و / أو أدوية خفض سكر الدم الفموية إلى تعديل.<br />&bull; إذا كان لديك مستوى منخفض من الصوديوم في الدم.<br />&bull; إذا كان لديك ميل لتطور النزيف أو الكدمات بسهولة.<br />&bull; إذا كنت تتلقى العلاج بالصدمة الكهربائية.<br />&bull; إذا كان لديك مرض القلب التاجي.<br />&bull; إذا كنت تعاني أو عانيت من مشاكل في القلب أو كان لديك مؤخراً نوبة قلبية.<br />&bull; إذا كان لديك أثناء الراحة معدل ضربات القلب منخفض و/ أو كنت تعرف أنك قد تعاني من نضوب<br />الملح نتيجة الإسهال الشديد والقيء لفترات طويلة (مريض) أو استخدام مدرات البول (أقراص الماء).<br />&bull; إذا كنت تعاني من عدم انتظام أو سرعة ضربات القلب، اغماء، هبوط أو دوخة عند الوقوف، مما قد<br />يشير إلى أداء غير طبيعي في معدل ضربات القلب.<br />&bull; إذا كان لديك أو كان لديك سابقا مشاكل في العين، مثل أنواع معينة من الزرق (زيادة الضغط في العين).<br />يرجى ملاحظة<br />بعض المرضى الذين يعانون من علة هوسية اكتئابية قد يدخلون إلى مرحلة الهوس. يتميز هذا بأفكارغير<br />عادية وسريعة التغير، سعادة غير ملائمة و فرط النشاط البدني. إذا واجهت هذه، اتصل بطبيبك.<br />لا تزال أعراض مثل التململ أو صعوبة في الجلوس أو الوقوف يمكن أيضا أن تحدث خلال الأسابيع<br />الأولى من العلاج. أخبر طبيبك فوراً إذا واجهت هذه الأعراض.<br />أفكار الانتحار وتفاقم الإكتئاب أو إضطرابات القلق لديك<br />إذا كنت مكتئبا و / أو لديك إضطرابات القلق يمكن أن يكون لديك في بعض الأحيان أفكار إيذاء أو قتل<br />نفسك. وهذه قد تزيد عند بدء أول مضادات للإكتئاب، لأن هذه الأدوية جميعها تأخذ وقت لتعمل، وعادة<br />حوالي أسبوعين لكن في بعض الأحيان لفترة أطول.<br />قد تكون أكثر عرضة للتفكير من هذا القبيل:<br />&bull; إذا كان لديك سابقاً أفكار حول قتل أو إيذاء نفسك.<br />&bull; إذا كنت من الشباب البالغين. وقد أظهرت المعلومات من التجارب السريرية زيادة خطر السلوك<br />الانتحاري لدى البالغين الذين تقل أعمارهم عن ۲٥ عاما و يعانون من حالات نفسية وعولجوا بمضادات<br />الإكتئاب.<br />إذا كان لديك أفكار إيذاء أو قتل نفسك في أي وقت، اتصل بطبيبك أو اذهب إلى المستشفى على الفور.<br />قد تجد أنه من المفيد أن تخبر قريب أو صديق مقرب إن كنت مكتئبا أو لديك إضطرابات القلق، وتطلب<br />منهم قراءة هذه النشرة. وقد تطلب منهم ان يخبروك إذا كانوا يعتقدون أن أعراض الإكتئاب أو القلق لديك<br />زادت سوءا، أو إذا كانوا قلقون بشأن تغيرات في السلوك الخاص بك.<br />الأطفال والمراهقين أقل من سن ۱۸ عام<br />للأطفال والمراهقين تحت سن ۱۸ عاما. أيضا، و يجب أن تعلم أن المرضى تحت &trade; عادة لايستخدم سيتابرو<br />سن ۱۸ عام تزيد لديهم مخاطر الآثار الجانبية مثل محاولات الانتحار، أفكار انتحارية و عدائية (عدوانية<br />غالباً ، سلوك عكسي و غضب) عندما يتناولون هذه الفئة من الأدوية. على الرغم من هذا، فإن طبيبك قد<br />&trade; للمرضى تحت سن ۱۸ عاما لأنه قرر بأن ذلك في صالحهم. إذا وصف طبيبك سيتابرو &trade; يصف سيتابرو<br />لمريض تحت سن ۱۸ عاما وتريد مناقشة هذا الموضوع، يرجى الرجوع إلى الطبيب. يجب إبلاغ الطبيب<br />إذا كان أي من الأعراض المذكورة أعلاه تتطور أو زادت سوءا عند المرضى الذين تقل أعمارهم عن<br />أيضا، لم يتم حتى الآن إثبات آثار السلامة على المدى الطويل بشأن النمو .&trade; ۱۸ عاما يتناولون سيتابرو<br />في هذه الفئة العمرية. &trade; والنضج والتطور المعرفي و السلوكي لسيتابرو<br />&trade; الأدوية الأخرى و سيتابرو<br />أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخرا أو قد تتناول أي أدوية أخرى.<br />أخبر طبيبك إذا كنت تتناول أي من الأدوية التالية:<br />التي تحتوي على فينلزين، إيبرونيازيد، ،&quot;(MAOIs) &bull; &quot;مثبطات المونامينو أوكسيديز غير انتقائية<br />إيزوكربوكسازيد، نيالاميد، وترانيلسيبرومين كمكونات نشطة و. إذا كنت قد تناولت أي من هذه الأدوية<br />يجب الانتظار ۷ أيام &trade; بعد وقف سيتابرو .&trade; سوف تحتاج إلى الانتظار ۱٤ يوما قبل البدء بتناول سيتابرو<br />قبل تناول أي من هذه الأدوية.<br />التي تحتوي على موكلوبميد ،&quot;MAO-A &bull; &quot; مثبطات المونامينو أوكسيديز انتقائية، عكسية<br />( تستخدم لعلاج الإكتئاب).<br />التي تحتوي على سيليجيلين ( تستخدم لعلاج ،&quot;MAO-B &bull; &quot;مثبطات المونامينو أوكسيديز غير العكسية<br />مرض باركنسون). و هذه تزيد من خطر الآثار الجانبية.<br />&bull; المضاد الحيوي لينيزوليد.<br />&bull; الليثيوم (يستخدم في علاج إضطراب الهوس الإكتئابي)، والتربتوفان.<br />&bull; إيميبرامين وديسيبرامين (كليهما يستخدمان لعلاج الإكتئاب).<br />&bull; سماتربتان والأدوية المشابهة ( تستخدم لعلاج الصداع النصفي) وترامادول (يستخدم ضد الآلام الحادة).<br />هذه تزيد من خطر الآثار الجانبية.<br />&bull; سيميتيدين، لانزوبرازول وأوميبرازول ( تستخدم لعلاج قرحة المعدة)، فلوفوكسامين (مضاد للإكتئاب)<br />وتيكلوبيدين (يستخدم للحد من خطر السكتة الدماغية). قد تسبب هذه الأدوية زيادة مستويات إس سيتالوبرام<br />في الدم.<br />&bull; سينت جونزورت (عشبة بيرفوراتوم) - علاج بالأعشاب يستخدم لعلاج الإكتئاب.<br />&bull; حمض أسيتيل الساليسيليك (الاسبرين) والعقاقير المضادة للالتهابات غير الإستيرويدية (الأدوية<br />المستخدمة لتخفيف الألم أو ترقيق الدم، ولذا تسمى مضادة الصفيحات). هذه قد تزيد قابلية النزيف.<br />&bull; وارفرين، ديبيريدامول، وفينوبروكومون ( أدوية تستخدم في ترقيق الدم، ما مضادات تجلط الدم). من<br />من أجل التحقق من أن الجرعة &trade; المحتمل أن يتحقق طبيبك من وقت تخثر الدم عند بدء و وقف سيتابرو<br />المضادة للتخثر ما زالت كافية.<br />&bull; ميفلوكين (يستخدم لعلاج الملاريا)، بوبروبيون (يستخدم لعلاج الإكتئاب)، ترامادول (يستخدم لعلاج الألم<br />الشديد) بسبب المخاطر المحتملة من خفض عتبة النوبات.<br />&bull; نيورولوبتك (أدوية لعلاج الفصام والذهان) ومضادات الإكتئاب (مضادات الإكتئاب ثلاثية الحلقات واس<br />اس اراي) بسبب المخاطر المحتملة من خفض عتبة النوبات.<br />&bull; فليسانيد، بروبافينون، و ميتوبرولول (تستخدم في أمراض القلب والأوعية الدموية) كلوميبرامين،<br />ونورتريبتيلين (مضادات الإكتئاب) وريسبيريدون، ثيوريدازين، وهالوبيريدول (مضادات الذهان). قد<br />إلى تعديل. &trade; تحتاج جرعة سيتابرو<br />&bull; الأدوية التي تقلل مستويات الدم من البوتاسيوم أو الماغنيسيوم، حيث أن هذه الحالات تزيد من خطر<br />إضطرابات نظم القلب المهددة للحياة.<br />إذا كنت تتناول أدوية لمشاكل نظم القلب أو أدوية يمكن أن تؤثر على نظم القلب، مثل &trade; لا تتناول سيتابرو<br />مضادات الذهان (مثل مشتقات الفينوثيازين، بيموزيد، ، III و IA مضادات إضطراب النظم من الفئة<br />هالوبيريدول)، مضادات الإكتئاب ثلاثية الحلقات، وبعض مضادات الميكروبات (على سبيل المثال<br />سبارفلوكساسين، موكسيفلوكساسين، اريثروميسين وريدي، بنتاميدين، أدوية مضادات الملاريا خاصة<br />هالوفانترين)، بعض مضادات الهيستامين (على سبيل المثال استيميزول، ميزولاستين ).<br />إذا كان لديك أي أسئلة أخرى حول هذا يجب عليك التحدث مع طبيبك.<br />مع الطعام و الشراب و الكحول &trade; سيتابرو<br />.(&trade; مع او بدون الطعام (انظر القسم ۳ &quot;كيفية تناول سيتابرو &trade; يمكن تناول سيتابرو<br />مع الكحول ، على الرغم من &trade; كما هو الحال مع العديد من الأدوية، ليس من المستحسن الجمع بين سيتابرو<br />مع الكحول. &trade; أنه ليس من المتوقع تفاعل سيتابرو<br />الحمل، الرضاعة و الخصوبة<br />إذا كنتِ حامل أو مرضعة، مالم &trade; أخبرى طبيبك إذا كنت حاملاً أو تخططين للحمل. لا تتناولي سيتابرو<br />تناقشي مع طبيبك الفوائد و المخاطر المحتملة التي قد تطرأ.<br />خلال أخر ۳ أشهرمن الحمل يجب أن تكونى على علم بأن الآثار التالية يمكن &trade; إذا كنت تناولتي سيتابرو<br />أن تُرى في المولود الجديد: صعوبة في التنفس، بشرة مزرقة، نوبات، تغييرات درجة حرارة الجسم،<br />صعوبة التغذية ، تقيؤ، انخفاض السكر في الدم ، تصلب أو مرونة العضلات، ردود فعل واضحة، رعاش،<br />عصبية، تهيج، خمول، بكاء مستمر، نعاس وصعوبات النوم. إذا كان المولود الجديد لديه أي من هذه<br />الأعراض، يرجى الاتصال بطبيبك على الفور.<br />خلال فترة &trade; عندما تتناولين أدوية مثل سيتابرو .&trade; تأكدى من أن طبيبك على علم أنك تتناولين سيتابرو<br />الحمل، خاصة في الثلاث أشهر الأخيرة من الحمل، قد تزيد من خطورة حالة جدية في الأطفال، وتسمى<br />تجعل الطفل يتنفس بشكل أسرع و يبدو ،(PPHN) إرتفاع ضغط الدم الرئوي المستمر لحديثي الولادة<br />مزرق اللون. عادة ما تبدأ هذه الأعراض خلال ال ۲٤ ساعة الأولى بعد ولادة الطفل. إذا حدث هذا لطفلك<br />يجب عليك الاتصال بطبيبك على الفور.<br />لا ينبغي أبدا التوقف فجأة. &trade; إذا ما استخدمت أثناء الحمل سيتابرو<br />في حليب الأم. &trade; من المتوقع أن يخرج سيتابرو<br />سيتالوبرام، وهو دواء مثل إس سيتالوبرام ، قد تبين أنه يقلل من كفاءة الحيوانات المنوية في الدراسات<br />على الحيوانات. و من الناحية النظرية، يمكن أن يؤثر هذا على الخصوبة، ولكن لم يلاحظ تأثير على<br />الخصوبة البشرية حتى الآن.<br />القيادة واستخدام الآلات<br />ينصح بعدم قيادة السيارة أو تشغيل الآلات حتى تعرف كيف تأثير سيتابرو&nbsp;عليك.&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائما بتناول هذاالدواء كما أخبرك طبيبك تماماً. يجب عليك مراجعة طبيبك أو الصيدلى إذا كنت غير<br />متأكد من طريقة الاستخدام.</p><p>الكبار<br />الإكتئابالجرعة الموصى بها عادة من سيتابرو هي ۱۰ ملجم كجرعة واحدة يومياً. يمكن زيادة الجرعة بواسطة&nbsp;الطبيب إلى ۲۰ ملجم كحد أقصى يومياً.</p><p>حالات الذعر:</p><p>الجرعة الأولية من سيتابرو&nbsp;هي ٥ ملجم في اليوم في الأسبوع الأول قبل زيادة الجرعة إلى&nbsp;۱۰ ملجم يومياً. يمكن زيادة الجرعة بواسطة الطبيب إلى ۲۰ ملجم كحد أقصى يومياً.</p><p>إضطراب القلق الإجتماعي:</p><p>الجرعة الموصى بها عادة من سيتابرو&nbsp;هي ۱۰ ملجم تؤخذ كجرعة واحدة يومياً.&nbsp;يمكن أن يقلل طبيبك الجرعة إلى ٥ ملجم يومياً أو يزيد الجرعة إلى ۲۰ ملجم كحد أقصى يومياً، على<br />حسب كيفية إستجابتك للدواء.</p><p>&nbsp;</p><p>ضطراب القلق العام:</p><p>الجرعة الموصى بها عادة من سيتابرو&nbsp;هي ۱۰ ملجم تؤخذ كجرعة واحدة يومياً. يمكن زيادة الجرعة&nbsp;بواسطة&nbsp; الطبيب إلى ۲۰ ملجم كحد أقصى يومياً.<br /><br />حالات الوسواس القهري:<br />&nbsp; الجرعة الموصى بها عادة من سيتابرو هي ۱۰ ملجم كجرعة واحدة يومياً. يمكن زيادة الجرعة بواسطة&nbsp;الطبيب إلى ۲۰ ملجم كحد أقصى يومياً.<br /><br />المرضى كبارالسن (فوق ٦٥ سنة من العمر)<br />الجرعة الأولية الموصي بها من سيتابروهي ٥ ملجم كجرعة واحدة يومياً. يمكن زيادة الجرعة بواسطة&nbsp;الطبيب إلى ۲۰ ملجم كحد أقصى يومياً.</p><p>الأطفال والمراهقين (أقل من ۱۸ سنة من العمر)<br />ل لمزيد من المعلومات الرجاء مراجعة &#39;&#39;&nbsp; قسم ۲ &#39;&#39;عادة لا ينبغي أن يعطى سيتابرو للأطفال والمراهقين.<br />. قبل أن تستخدم سيتابرو<br />مع الطعام أو بدونه . ابتلع القرص مع بعض الماء. لا تمضغ الأقراص، &trade; يمكنك أن تتناول سيتابرو<br />فهي مرة الطعم.<br />إذا لزم الأمر، يمكنك تقسيم الأقراص أولا عن طريق وضع القرص على سطح مستو مع وضع الجانب<br />الذى به خط الكسرمواجه لأعلى. بعد ذلك يمكن كسر القرص عن طريق الضغط على نهايتى القرص،<br />بإستخدام كلا السبابتين.<br />مدة العلاج<br />حتى لو استغرق ذلك &trade; قد يتطلب الأمر أسبوعين قبل أن تبدأ في الشعور بالتحسن. استمر فى تناول سيتابرو<br />بعض الوقت قبل أن تشعر بأي تحسن في حالتك.<br />لا تغير جرعة دوائك دون استشارة طبيبك أولا.<br />طالما أوصي طبيبك بذلك. إذا قمت بإيقاف العلاج مبكراً، قد تعود الأعراض. &trade; استمر فى تناول سيتابرو<br />من المستحسن أن يستمر العلاج على الأقل لمدة ٦ أشهر بعد شعورك بالتحسن مرة أخرى.<br />أكثر مما يجب &trade; إذا كنت تناولت المزيد من سيتابرو<br />اتصل بطبيبك أو أقرب قسم طوارئ بأقرب ،&trade; إذا كنت تناولت أكثر من الجرعة الموصوفة من سيتابرو<br />مستشفى فوراً. قم بذلك حتى إذا لم تكن هناك أي علامات. بعض من علامات الجرعة الزائدة قد تكون<br />الدوخة، ورعاش، هيجان،<br />تشنج، غيبوبة، غثيان، قيء، تغير في ضربات القلب، انخفاض ضغط الدم<br />عند الذهاب إلى الطبيب أو المستشفى. &trade; وتغيير في توازن السوائل / الملح بالجسم . خذ معك علبة سيتابرو<br />&trade; إذا كنت قد نسيت أن تتناول سيتابرو<br />لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. إذا نسيت تناول جرعة، وتذكرت قبل أن تذهب إلى<br />النوم، تناولها على الفور. و استمر كالمعتاد في اليوم التالي. إذا كنت قد تذكرت فقط أثناء الليل، أو في اليوم<br />التالي، أترك الجرعة المنسية و استمر كالمعتاد.<br />&trade; إذا كنت قد توقفت عن تناول سيتابرو<br />حتى يطلب منك طبيبك أن تفعل ذلك. عندما تكمل فترتك العلاجية ، ينصح &trade; لا تتوقف عن تناول سيتابرو<br />تدريجياً على مدى عدة أسابيع. &trade; عموماً أن يتم تقليل جرعة سيتابرو<br />خاصة إذا كان فجأة، قد تشعر بأعراض التوقف. وهذه الأعراض شائعة ،&trade; عند التوقف عن تناول سيتابرو<br />لفترة طويلة أو بجرعات عالية أو &trade; والخطورة أعلى، إذا تم استخدام سيتابرو .&trade; عند توقف العلاج بسيتابرو<br />عندما يتم خفض الجرعة بسرعة كبيرة جدا. معظم الناس يجدون أن الأعراض خفيفة وتزول من تلقاء<br />نفسها في غضون أسبوعين. ومع ذلك، في بعض المرضى قد تكون شديدة الحدة أو قد تكون لفترات طويلة<br />يرجى الاتصال ،&trade; ۳ أشهر أو أكثر). اذا كان لديك أعراض إيقاف حادة عند التوقف عن تناول سيتابرو -۲)<br />بطبيبك. فقد يطلب منك البدء في تناول أقراصك مرة أخرى ثم تقللها بشكل أكثر بطء.<br />وتشمل أعراض التوقف: الشعور بالدوار (غير مستقر أو غير متوازن)، شعور مثل الدبابيس والإبر،<br />إحساس بالحرقان و(أقل شيوعا) إحساس بصدمة كهربائية، بما في ذلك الرأس، إضطرابات النوم (أحلام<br />اليقظة، كوابيس، عدم القدرة على النوم)، الشعور بالقلق، الصداع، الشعور بالمرض (الغثيان)، التعرق (بما<br />في ذلك تعرق ليلي)، الشعور بعدم الراحة و الهياج، رعاش (اهتزاز)، الشعور بالإرتباك أو التشوش،<br />الشعور بالعاطفة أو تعكر المزاج، إسهال (براز رخو)، إضطرابات بصرية، ترفرف أو خفقان نبض القلب.<br />إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، إسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثار جانبية، بالرغم من أنه ليس كل شخص يتأثر بتلك الآثار .<br />الآثار الجانبية عادة ما تختفي بعد بضعة أسابيع من العلاج. يرجى أن تكون على علم بأن العديد من الآثار<br />قد تكون أعراض لمرضك أيضا، و لهذا تقل عندما تبدأ في التحسن.<br />إذا كنت واجهت أي من الأعراض التالية يجب عليك الاتصال بطبيبك أو إذهب إلى المستشفى على الفور:<br />غير شائعة ( قد تؤثر على ما يصل إلى ۱ لكل ۱۰۰ شخص ):<br />&bull; نزيف غير عادي، بما في ذلك نزيف الجهاز الهضمي.<br />نادرة ( قد تؤثر على ما يصل إلى ۱ لكل ۱۰۰۰ شخص ):<br />&bull; تورم الجلد، اللسان، الشفاه أو الوجه، أو حدوث صعوبات في التنفس أو البلع ( تفاعلات حساسية).<br />&bull; ارتفاع درجة الحرارة، التهيج، التشوش، الرجفان وانقباض العضلات المفاجئ قد تكون علامات لحالة<br />نادرة تسمى متلازمة السيروتونين.<br />غير معروفة ( لا يمكن تقدير ترددها من البيانات المتاحة ):<br />&bull; صعوبات في التبول<br />&bull; نوبات ، راجع أيضا القسم ۲ &quot;تحذيرات و احتياطات&quot;<br />&bull; اصفرار البشرة و الجزء الابيض في العينين هي علامات لخلل وظائف الكبد / التهاب الكبد<br />&bull; ضربات قلب سريعة، غير منتظمة، الإغماء التي يمكن أن تكون أعراض حالة تهدد الحياة تعرف باسم<br />.torsade de pointes تورساد دي بوينتس<br />&bull; أفكار حول إيذاء أو قتل نفسك، انظر أيضا القسم ۲ &quot;تحذيرات و احتياطات&quot;<br />بالإضافة إلى ما سبق تم الإبلاغ عن الآثار الجانبية التالية :<br />شائعة جدا ( قد تؤثر على أكثر من ۱ لكل ۱۰ أشخاص ):<br />&bull; الشعور بالمرض<br />(الغثيان)<br />&bull; الصداع<br />شائعة ( قد تؤثر على ما يصل إلى ۱ لكل ۱۰ أشخاص ):<br />&bull; إنسداد أو سيلان الأنف (التهاب الجيوب الأنفية)<br />&bull; فقدان أو زيادة الشهية<br />&bull; القلق، الأرق، أحلام غير عادية، صعوبة في النوم، الشعور بالنعاس، الدوار، تثاؤب، رعشة، قشعريرة<br />في الجلد<br />&bull; إسهال ، إمساك، التقيؤ وجفاف الفم<br />&bull; زيادة التعرق<br />&bull; ألم في العضلات والمفاصل (ألم مفصلي وألم عضلي)<br />&bull; إضطرابات جنسية ( تأخر القذف، مشاكل في الانتصاب، تقليل الرغبة الجنسية و قد تجد النساء صعوبة<br />في الوصول إلى ذروة الجماع)<br />&bull; الإرهاق، الحمى<br />&bull; زيادة الوزن<br />غير شائعة ( قد تؤثر على ما يصل إلى ۱ من كل ۱۰۰ شخص ):<br />&bull; طفح القراص (الشرى)، والطفح الجلدي، الحكة<br />&bull; صرير الأسنان، تهيج، عصبية، نوبات ذعر و ارتباك<br />&bull; إضطرابات النوم، إضطرابات التذوق، إغماء (الغشيان)<br />&bull; إتساع بؤبؤ العين (توسع حدقة العين)، إضطرابات بصرية، طنين في الأذنين (طنين)<br />&bull; فقدان الشعر<br />&bull; عدم انتظام فترة الحيض<br />&bull; نزيف حيض مفرط<br />&bull; انخفاض الوزن<br />&bull; تورم في الذراعين أو الساقين<br />&bull; نزيف الأنف<br />نادرة ( قد تؤثر على ما يصل إلى ۱ من كل ۱۰۰۰ شخص ):<br />&bull; عدوانية، ضياع الشخصية، هلوسة<br />&bull; بطء ضربات القلب<br />غير معروفة (لا يمكن تقدير ترددها من البيانات المتاحة):<br />&bull; انخفاض مستويات الصوديوم في الدم (الأعراض هي الشعور بالإعياء مع ضعف العضلات و التشوش)<br />&bull; الدوار عند الوقوف بسبب انخفاض ضغط الدم (هبوط ضغط الدم الانتصابي)<br />&bull; خلل في وظائف الكبد المعملية (زيادة كميات الانزيمات الكبدية في الدم)<br />&bull; إضطرابات الحركة (حركات لا إرادية للعضلات)<br />&bull; انتصاب مؤلم (قساح)<br />&bull; علامات زيادة النزيف على سبيل المثال من البشرة والأغشية المخاطية (كدمات)<br />&bull; تورم مفاجئ من الجلد أو الغشاء المخاطي (وذمة وعائية)<br />غير مناسب ) ADH &bull; زيادة في كمية البول المخرج ( إفراز<br />&bull; إنسياب الحليب لدى الرجال ولدى النساء غير المرضعات<br />&bull; هوس<br />&bull; وقد لوحظ زيادة خطر كسور العظام في المرضى الذين يتناولون هذا النوع من الأدوية<br />يظهر على تخطيط القلب، الذي يقيس ،&quot;QT &bull; تغيرات في ضربات القلب (وتسمى &quot;إطالة فترة الاستقطاب<br />النشاط الكهربائي للقلب).<br />بالإضافة إلى ذلك، من المعروف عدد من الآثار الجانبية تحدث مع الأدوية التي تعمل بطريقة مماثلة ل إس<br />وهذه هي: .(&trade; سيتالوبرام (المادة الفعالة في سيتابرو<br />&bull; التململ الحركي (تعذر الجلوس)<br />&bull; فقدان الشهية.<br />قم بالإتصال بطبيبك المعالج أو الصيدلي في حال زيادة حدة الأعراض الجانبية أو الاصابة بعرض<br />جانبي لم يتم ذكره في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ بعيداً عن متناول و مرأى الأطفال.<br />&bull; يحفظ فى درجة حرارة لا تزيد عن ۳۰&nbsp;م &ordm;.<br />بعد انتهاء فترة صلاحيتها المكتوب على الشرائط وعلى العلبة. &trade; &bull; لا تتناول أقراص سيتابرو<br />&bull; إسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها. لا ينبغي التخلص من الأدوية عبر<br />إلقائها فى بالوعات الصرف أو فى مخلفات المنزل . ستساعد هذه التدابير في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي إس سيتالوبرام<br />سيتابرو ۱۰ ملجم أقراص: كل قرص مغلف يحتوي على ۱۰ ملجم إس سيتالوبرام (أوكساليت).&nbsp;&nbsp;<br />سيتابرو ۲۰ ملجم أقراص: كل قرص مغلف يحتوي على ۲۰ ملجم إس سيتالوبرام (أوكساليت).<br />المكونات الأخرى هي:<br />القرص الأساسي: سيليلوز دقيق التبلور ، تلك، صمغي ثاني أكسيد السيليكون، كروسكارميلوز الصوديوم و<br />ستيرات الماغنيسيوم.<br />الغلاف: أبادري أبيض (الذي يحتوي، هيبروميلوز، ثاني أكسيد التيتانيوم، بروبيلين جليكول والتلك).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">&bull; سيتابرو ۱۰ ملجم أقراص: لونها أبيض إلى مائل للأبيض، بيضاوية، محدبة الوجهين مغلفة، محفور &quot;JP119&quot;على أحد الوجهين&nbsp;وخط الكسر علي الجانب الآخر.</p><p style="text-align:right">&bull; سيتابرو ۱۰ ملجم أقراص: لونها أبيض إلى مائل للأبيض، بيضاوية، محدبة الوجهين مغلفة، محفور &quot;JP120&quot;على أحد الوجهين&nbsp;وخط الكسر علي الجانب الآخر.</p><p style="text-align:right"><br />&bull; سيتابرو ۱۰ ملجم أقراص متوفرة فى عبوة تحتوي على ۳۰ قرص مغلف.&nbsp;<br />&bull; سيتابرو ۲۰ ملجم أقراص متوفرة فى عبوة تحتوي على ۳۰ قرص مغلف.&nbsp;<br />قد لا تكون كل العبوات مسوقة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدوية المحدودة، جدة، المملكة العربية السعودية<br />- الهاتف: 608111-12-966+ فاكس :&nbsp;608222-12-966+<br />الموقع الإلكتروني:&nbsp;www.jamjoompharma.com&nbsp;<br />للإبلاغ عن أي أثار جانبيه:<br />&bull; المملكة العربية السعودية:<br />المركز الوطني للتيقظ و السلامة الدوائية<br />- فاكس: 7662-205-11-966+&nbsp;<br />للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات.<br />هاتف: 22228302-11-966+ تحويلة: 2317-2356-2353-2354-2334-2340<br />الهاتف المجاني: 8002490000<br />بريد إلكتروني:&nbsp;npc.drug@sfda.gov.sa<br />الموقع الالكتروني:&nbsp;www.sfda.gov.sa/npc<br />&bull; دول الخليج الأخرى:<br />الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Setapro 10 mg Film Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 10 mg Escitalopram (as oxalate)
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
White to off white, oval, biconvex, film coated tablets, engraved with 'JP 119 on one side and break
line on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of major depressive episodes.<br />Treatment of panic disorder with or without agoraphobia.<br />Treatment of social anxiety disorder (social phobia).<br />Treatment of generalized anxiety disorder.<br />Treatment of obsessive-compulsive disorder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Safety of daily doses above 20 mg has not been demonstrated.<br />Setapro is administered as a single daily dose and may be taken with or without food.</p><p>Major depressive episodes<br />Usual dosage is 10 mg once daily. Depending on individual patient response, the dose may be<br />increased to a maximum of 20 mg daily.<br />Usually 2-4 weeks are necessary to obtain antidepressant response. After the symptoms resolve,<br />treatment for at least 6 months is required for consolidation of the response.<br />Panic disorder with or without agoraphobia<br />An initial dose of 5 mg is recommended for the first week before increasing the dose to 10 mg<br />daily. The dose may be further increased, up to a maximum of 20 mg daily, dependent on<br />individual patient response.<br />Maximum effectiveness is reached after about 3 months. The treatment lasts several months.<br />Social anxiety disorder<br />Usual dosage is 10 mg once daily. Usually 2-4 weeks are necessary to obtain symptom relief. The<br />dose may subsequently, depending on individual patient response, be decreased to 5 mg or<br />increased to a maximum of 20 mg daily.<br />Social anxiety disorder is a disease with a chronic course, and treatment for 12 weeks is<br />recommended to consolidate response. Long-term treatment of responders has been studied for 6<br />months and can be considered on an individual basis to prevent relapse; treatment benefits should<br />be re-evaluated at regular intervals.<br />Social anxiety disorder is a well-defined diagnostic terminology of a specific disorder, which<br />should not be confounded with excessive shyness. Pharmacotherapy is only indicated if the<br />disorder interferes significantly with professional and social activities.<br />The place of this treatment compared to cognitive behavioral therapy has not been assessed.<br />Pharmacotherapy is part of an overall therapeutic strategy.</p><p>Generalised anxiety disorder<br />Initial dosage is 10 mg once daily. Depending on the individual patient response, the dose may be<br />increased to a maximum of 20 mg daily.<br />Long-term treatment of responders has been studied for at least 6 months in patients receiving 20<br />mg daily. Treatment benefits and dose should be re-evaluated at regular intervals.<br />Obsessive-compulsive disorder<br />Initial dosage is 10 mg once daily. Depending on the individual patient response, the dose may be<br />increased to a maximum of 20 mg daily.<br />As OCD is a chronic disease, patients should be treated for a sufficient period to ensure that they<br />are symptom free.<br />Treatment benefits and dose should be re-evaluated at regular intervals.<br />Elderly patients (&gt; 65 years of age)<br />Initial dosage is 5 mg once daily. Depending on individual patient response the dose may be<br />increased to 10 mg daily.<br />The efficacy of Escitalopram in social anxiety disorder has not been studied in elderly patients.<br />Children and adolescents (&lt;18 years)<br />Setapro should not be used in the treatment of children and adolescents under the age of 18 years.<br />Reduced renal function<br />Dosage adjustment is not necessary in patients with mild or moderate renal impairment. Caution is<br />advised in patients with severely reduced renal function (CLCR less than 30 ml/min.).<br />Reduced hepatic function<br />An initial dose of 5 mg daily for the first two weeks of treatment is recommended in patients with<br />mild or moderate hepatic impairment. Depending on individual patient response, the dose may be<br />increased to 10 mg daily. Caution and extra careful dose titration is advised in patients with<br />severely reduced hepatic function.<br />Poor metabolisers of CYP2C19<br />For patients who are known to be poor metabolisers with respect to CYP2C19, an initial dose of 5<br />mg daily during the first two weeks of treatment is recommended. Depending on individual patient<br />response, the dose may be increased to 10 mg daily.</p><p>Discontinuation symptoms seen when stopping treatment<br />Abrupt discontinuation should be avoided. When stopping treatment with Escitalopram the dose<br />should be gradually reduced over a period of at least one to two weeks in order to reduce the risk<br />of discontinuation symptoms. If intolerable symptoms occur following a decrease in the dose or<br />upon discontinuation of treatment, then resuming the previously prescribed dose may be<br />considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual<br />rate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients, listed in section 6.1.
Concomitant treatment with non-selective, irreversible monoamine oxidase inhibitors (MAOinhibitors)
is contraindicated due to the risk of serotonin syndrome with agitation, tremor,
hyperthermia etc.
The combination of Escitalopram with reversible MAO-A inhibitors (e.g. moclobemide) or the
reversible non-selective MAO-inhibitor linezolid is contraindicated due to the risk of onset of a
serotonin syndrome.
Escitalopram is contraindicated in patients with known QT interval prolongation or congenital
long QT syndrome.
Escitalopram is contraindicated together with medicinal products that are known to prolong the
QT interval.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following special warnings and precautions apply to the therapeutic class of SSRIs (Selective<br />Serotonin Re-uptake Inhibitors).<br />Use in children and adolescents under 18 years of age<br />Setapro should not be used in the treatment of children and adolescents under the age of 18 years.<br />Suicide related behaviors (suicide attempt and suicidal thoughts), and hostility (predominately<br />aggression, oppositional behavior and anger) were more frequently observed in clinical trials<br />among children and adolescents treated with antidepressants compared to those treated with<br />placebo.<br />If, based on clinical need, a decision to treat is nevertheless taken; the patient should be carefully<br />monitored for the appearance of suicidal symptoms. In addition, long-term safety data in children<br />and adolescents concerning growth, maturation and cognitive and behavioral development are<br />lacking.</p><p>Paradoxical anxiety<br />Some patients with panic disorder may experience increased anxiety symptoms at the beginning of<br />treatment with antidepressants. This paradoxical reaction usually subsides within two weeks<br />during continued treatment. A low starting dose is advised to reduce the likelihood of an<br />anxiogenic effect.<br />Seizures<br />Escitalopram should be discontinued if a patient develops seizures for the first time, or if there is<br />an increase in seizure frequency (in patients with a previous diagnosis of epilepsy). SSRIs should<br />be avoided in patients with unstable epilepsy, and patients with controlled epilepsy should be<br />closely monitored.<br />Mania<br />SSRIs should be used with caution in patients with a history of mania/hypomania. SSRIs should be<br />discontinued in any patient entering a manic phase.<br />Diabetes<br />In patients with diabetes, treatment with an SSRI may alter glycaemic control (hypoglycaemia or<br />hyperglycaemia). Insulin and/or oral hypoglycaemic dosage may need to be adjusted.<br />Suicide/suicidal thoughts or clinical worsening<br />Depression is associated with an increased risk of suicidal thoughts, self harm and suicide<br />(suicide-related events). This risk persists until significant remission occurs. As improvement may<br />not occur during the first few weeks or more of treatment, patients should be closely monitored<br />until such improvement occurs. It is general clinical experience that the risk of suicide may<br />increase in the early stages of recovery.<br />Other psychiatric conditions for which Setapro is prescribed can also be associated with an<br />increased risk of suicide-related events. In addition, these conditions may be co-morbid with major<br />depressive disorder. The same precautions observed when treating patients with major depressive<br />disorder should therefore be observed when treating patients with other psychiatric disorders.<br />Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal<br />ideation prior to commencement of treatment, are known to be at greater risk of suicidal thoughts<br />or suicide attempts, and should receive careful monitoring during treatment. A meta analysis of<br />placebo controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders<br />showed an increased risk of suicidal behaviour with antidepressants compared to placebo in<br />patients less than 25 years old. Close supervision of patients and in particular those at high risk<br />should accompany drug therapy especially in early treatment and following dose changes.</p><p>Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical<br />worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical<br />advice immediately if these symptoms present.<br />Akathisia/psychomotor restlessness<br />The use of SSRIs/SNRIs has been associated with the development of akathisia, characterised by a<br />subjectively unpleasant or distressing restlessness and need to move often accompanied by an<br />inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In<br />patients who develop these symptoms, increasing the dose may be detrimental.<br />Hyponatraemia<br />Hyponatraemia, probably due to inappropriate antidiuretic hormone secretion (SIADH), has been<br />reported rarely with the use of SSRIs and generally resolves on discontinuation of therapy.<br />Caution should be exercised in patients at risk, such as the elderly, or patients with cirrhosis, or if<br />used in combination with other medications which may cause hyponatraemia.<br />Haemorrhage<br />There have been reports of cutaneous bleeding abnormalities, such as ecchymoses and purpura,<br />with SSRIs. Caution is advised in patients taking SSRIs, particularly in concomitant use with oral<br />anticoagulants, with medicinal products known to affect platelet function (e.g. atypical<br />antipsychotics and phenothiazines, most tricyclic antidepressants, acetylsalicylic acid and nonsteroidal<br />anti-inflammatory medicinal products (NSAIDs), ticlopidine and dipyridamole) and in<br />patients with known bleeding tendencies.<br />ECT (electroconvulsive therapy)<br />There is limited clinical experience of concurrent administration of SSRIs and ECT, therefore<br />caution is advisable.<br />Serotonin syndrome<br />Caution is advisable if Escitalopram is used concomitantly with medicinal products with<br />serotonergic effects such as sumatriptan or other triptans, tramadol and tryptophan.<br />In rare cases, serotonin syndrome has been reported in patients using SSRIs concomitantly with<br />serotonergic medicinal products. A combination of symptoms, such as agitation, tremor,<br />myoclonus and hyperthermia may indicate the development of this condition. If this occurs<br />treatment with the SSRI and the serotonergic medicinal product should be discontinued<br />immediately and symptomatic treatment initiated.<br />St. John&#39;s wort<br />Concomitant use of SSRIs and herbal remedies containing St. John&#39;s wort (Hypericum perforatum)<br />may result in an increased incidence of adverse reactions.</p><p>Discontinuation symptoms seen when stopping treatment<br />Discontinuation symptoms when stopping treatment are common, particularly if discontinuation is<br />abrupt. In clinical trials adverse events seen on treatment discontinuation occurred in<br />approximately 25% of patients treated with Escitalopram and 15% of patients taking placebo.<br />The risk of discontinuation symptoms may be dependent on several factors including the duration<br />and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including<br />paraesthesia and electric shock sensations), sleep disturbances (including insomnia and intense<br />dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache,<br />diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most<br />commonly reported reactions. Generally these symptoms are mild to moderate, however, in some<br />patients they may be severe in intensity.<br />They usually occur within the first few days of discontinuing treatment, but there have been very<br />rare reports of such symptoms in patients who have inadvertently missed a dose.<br />Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some<br />individuals they may be prolonged (2-3 months or more). It is therefore advised that escitalopram<br />should be gradually tapered when discontinuing treatment over a period of several weeks or<br />months, according to the patient&#39;s needs (see &ldquo;Discontinuation symptoms seen when stopping<br />treatment&rdquo;.<br />Coronary heart disease<br />Due to limited clinical experience, caution is advised in patients with coronary heart disease.<br />QT interval prolongation<br />Escitalopram has been found to cause a dose-dependent prolongation of the QT interval. Cases of<br />QT interval prolongation and ventricular arrhythmia including torsade de pointes have been<br />reported during the post-marketing period, predominantly in patients of female gender, with<br />hypokalaemia, or with pre-existing QT interval prolongation or other cardiac diseases.<br />Caution is advised in patients with significant bradycardia; or in patients with recent acute<br />myocardial infarction or uncompensated heart failure.<br />Electrolyte disturbances such as hypokalaemia and hypomagnesaemia increase the risk for<br />malignant arrhythmias and should be corrected before treatment with Escitalopram is started.<br />If patients with stable cardiac disease are treated, an ECG review should be considered before<br />treatment is started.<br />If signs of cardiac arrhythmia occur during treatment with Escitalopram, the treatment should be<br />withdrawn and an ECG should be performed.</p><p>Angle-Closure Glaucoma<br />SSRIs including Escitalopram may have an effect on pupil size resulting in mydriasis. This<br />mydriatic effect has the potential to narrow the eye angle resulting in increased intraocular<br />pressure and angle-closure glaucoma, especially in patients pre-disposed. Escitalopram should<br />therefore be used with caution in patients with angle-closure glaucoma or history of glaucoma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic interactions<br />Contraindicated combinations:<br />Irreversible non-selective MAOIs<br />Cases of serious reactions have been reported in patients receiving an SSRI in combination with a<br />non-selective, irreversible monoamine oxidase inhibitor (MAOI), and in patients who have<br />recently discontinued SSRI treatment and have been started on such MAOI treatment. In some<br />cases, the patient developed serotonin syndrome.<br />Escitalopram is contraindicated in combination with non-selective, irreversible MAOIs.<br />Escitalopram may be started 14 days after discontinuing treatment with an irreversible MAOI. At<br />least 7 days should elapse after discontinuing escitalopram treatment, before starting a nonselective,<br />irreversible MAOI.<br />Reversible, selective MAO-A inhibitor (moclobemide)<br />Due to the risk of serotonin syndrome, the combination of escitalopram with a MAO-A inhibitor<br />such as moclobemide is contraindicated. If the combination proves necessary, it should be started<br />at the minimum recommended dosage and clinical monitoring should be reinforced.<br />Reversible, non-selective MAO-inhibitor (linezolid)<br />The antibiotic linezolid is a reversible non-selective MAO-inhibitor and should not be given to<br />patients treated with escitalopram. If the combination proves necessary, it should be given with<br />minimum dosages and under close clinical monitoring.<br />Irreversible, selective MAO-B inhibitor (selegiline)<br />In combination with selegiline (irreversible MAO-B inhibitor), caution is required due to the risk<br />of developing serotonin syndrome. Selegiline doses up to 10 mg/day have been safely coadministered<br />with racemic citalopram.</p><p>QT interval prolongation<br />Pharmacokinetic and pharmacodynamic studies of escitalopram combined with other medicinal<br />products that prolong the QT interval have not been performed. An additive effect of escitalopram<br />and these medicinal products cannot be excluded. Therefore, co-administration of escitalopram<br />with medicinal products that prolong the QT interval, such as Class IA and III antiarrhythmics,<br />antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants,<br />certain antimicrobial agents (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, antimalarial<br />treatment particularly halofantrine), certain antihistamines (e.g. astemizole, mizolastine),<br />is contraindicated.<br />Combinations requiring precautions for use:<br />Serotonergic medicinal products<br />Co-administration with serotonergic medicinal products (e.g. tramadol, sumatriptan and other<br />triptans) may lead to serotonin syndrome.<br />Medicinal products lowering the seizure threshold<br />SSRIs can lower the seizure threshold. Caution is advised when concomitantly using other<br />medicinal products capable of lowering the seizure threshold (e.g antidepressants (tricyclics,<br />SSRIs), neuroleptics (phenothiazines, thioxanthenes and butyrophenones), mefloquin, bupropion<br />and tramadol).<br />Lithium, tryptophan<br />There have been reports of enhanced effects when SSRIs have been given together with lithium or<br />tryptophan, therefore concomitant use of SSRIs with these medicinal products should be<br />undertaken with caution.<br />St. John&#39;s wort<br />Concomitant use of SSRIs and herbal remedies containing St. John&acute;s wort (Hypericum<br />perforatum) may result in an increased incidence of adverse reactions.<br />Haemorrhage<br />Altered anti-coagulant effects may occur when escitalopram is combined with oral anticoagulants.<br />Patients receiving oral anticoagulant therapy should receive careful coagulation monitoring when<br />Escitalopram is started or stopped. Concomitant use of non-steriodal anti-inflammatory drugs<br />(NSAIDs) may increase bleeding-tendency.</p><p>Alcohol<br />No pharmacodynamic or pharmacokinetic interactions are expected between escitalopram and<br />alcohol. However, as with other psychotropic medicinal products, the combination with alcohol is<br />not advisable.<br />Medicinal products inducing hypokalaemia/hypomagnesaemia<br />Caution is warranted for concomitant use of hypokalaemia/hypomagnesaemia inducing medicinal<br />products as these conditions increase the risk of malignant arrhythmias.<br />Pharmacokinetic interactions<br />Influence of other medicinal products on the pharmacokinetics of Escitalopram<br />The metabolism of Escitalopram is mainly mediated by CYP2C19. CYP3A4 and CYP2D6 may<br />also contribute to the metabolism although to a smaller extent. The metabolism of the major<br />metabolite S-DCT (demethylated escitalopram) seems to be partly catalysed by CYP2D6.<br />Co-administration of Escitalopram with omeprazole 30 mg once daily (a CYP2C19 inhibitor)<br />resulted in moderate (approximately 50%) increase in the plasma concentrations of Escitalopram.<br />Co-administration of Escitalopram with cimetidine 400 mg twice daily (moderately potent general<br />enzyme-inhibitor) resulted in a moderate (approximately 70%) increase in the plasma<br />concentrations of Escitalopram. Caution is advised when administering escitalopram in<br />combination with cimetidine. Dose adjustment may be warranted.<br />Thus, caution should be exercised when used concomitantly with CYP2C19 inhibitors (e.g.<br />omeprazole, esomeprazole, fluvoxamine, lansoprazole, ticlopidine) or cimetidine. A reduction in<br />the dose of escitalopram may be necessary based on monitoring of side-effects during concomitant<br />treatment.<br />Effect of Escitalopram on the pharmacokinetics of other medicinal products:<br />Escitalopram is an inhibitor of the enzyme CYP2D6. Caution is recommended when Escitalopram<br />is co-administered with medicinal products that are mainly metabolised by this enzyme, and that<br />have a narrow therapeutic index, e.g. flecainide, propafenone and metoprolol (when used in<br />cardiac failure), or some CNS acting medicinal products that are mainly metabolised by CYP2D6,<br />e.g. antidepressants such as desipramine, clomipramine and nortriptyline or antipsychotics like<br />risperidone, thioridazine and haloperidol. Dosage adjustment may be warranted.<br />Co-administration with desipramine or metoprolol resulted in both cases in a twofold increase in<br />the plasma levels of these two CYP2D6 substrates.</p><p>In vitro studies have demonstrated that Escitalopram may also cause weak inhibition of CYP2C19.<br />Caution is recommended with concomitant use of medicinal products that are metabolised by<br />CYP2C19.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy Category C<br />Pregnancy<br />For Escitalopram only limited clinical data are available regarding exposed pregnancies.<br />Animal studies have shown reproductive toxicity. Setapro should not be used during pregnancy<br />unless clearly necessary and only after careful consideration of the risk/benefit.<br />Neonates should be observed if maternal use of Setapro continues into the later stages of<br />pregnancy, particularly in the third trimester. Abrupt discontinuation should be avoided during<br />pregnancy.<br />The following symptoms may occur in the neonate after maternal SSRI/SNRI use in later stages of<br />pregnancy: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding<br />difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness,<br />irritability, lethargy, constant crying, somnolence and difficulty sleeping. These symptoms could<br />be due to either serotonergic effects or discontinuation symptoms. In a majority of instances the<br />complications begin immediately or soon (&lt;24 hours) after delivery.<br />Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late<br />pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN).<br />The observed risk was approximately 5 cases per 1000 pregnancies. In the general population 1 to<br />2 cases of PPHN per 1000 pregnancies occur.<br />Breast-feeding<br />It is expected that Escitalopram will be excreted into human milk. Consequently, breast-feeding is<br />not recommended during treatment.<br />Fertility<br />Animal data have shown that citalopram may affect sperm quality. Human case reports with some<br />SSRIs have shown that an effect on sperm quality is reversible. Impact on human fertility has not<br />been observed so far.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although Escitalopram has been shown not to affect intellectual function or psychomotor<br />performance, any psychoactive medicinal product may impair judgement or skills. Patients should<br />be cautioned about the potential risk of an influence on their ability to drive a car and operate<br />machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are most frequent during the first or second week of treatment and usually<br />decrease in intensity and frequency with continued treatment.<br />Tabulated list of adverse reactions<br />Adverse reactions known for SSRIs and also reported for Escitalopram in either placebocontrolled<br />clinical studies or as spontaneous post-marketing events are listed below by system<br />organ class and frequency.<br />Frequencies are taken from clinical studies; they are not placebo-corrected. Frequencies are<br />defined as: very common (􀂕1/10), common (􀂕1/100 to &lt;1/10), uncommon (􀂕1/1,000 to &lt;1/100),<br />rare (􀂕1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), or not known (cannot be estimated from the<br />available data).</p><p><img alt="" height="648" width="745" src="data:image/png;base64,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" /><br /><img alt="" height="801" width="747" src="data:image/png;base64,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" /></p><p>These events have been reported for the therapeutic class of SSRIs.</p><p>2 Cases of suicidal ideation and suicidal behaviours have&nbsp; been&nbsp; reported&nbsp; during&nbsp; Escitalopram&nbsp; therapy or early after treatment discontinuation.</p><p><u>QT interval prolongation</u></p><p>Cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period, predominantly in patients of female gender, with hypokalaemia, or with pre-existing QT interval prolongation or other cardiac diseases (see sections 4.3, 4.4, 4.5, 4.9 and 5.1).</p><p><u>Class effects</u></p><p>Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.</p><p><u>Discontinuation symptoms seen when stopping treatment</u></p><p>Discontinuation of SSRIs/SNRIs (particularly when abrupt) commonly leads to discontinuation symptoms. Dizziness, sensory disturbances (including paraesthesia and electric shock sensations), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally these events are mild to moderate and are self-limiting, however, in some patients they may be severe and/or prolonged. It is therefore advised that when Escitalopram treatment is no longer required, gradual discontinuation by dose tapering should be carried out.</p><p>To report any side effect(s):</p><p>&bull;&nbsp; <strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: &nbsp;npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1 <u>Toxicity</u></p><p>Clinical data on Escitalopram overdose are limited and many cases involve concomitant overdoses of other drugs. In the majority of cases mild or no symptoms have been reported. Fatal cases of Escitalopram overdose have rarely been reported with Escitalopram alone; the majority of cases have involved overdose with concomitant medications. Doses between 400 and 800 mg of Escitalopram alone have been taken without any severe symptoms.</p><p><u>Symptoms</u></p><p>Symptoms seen in reported overdose of Escitalopram include symptoms mainly related to the central nervous system (ranging from dizziness, tremor, and agitation to rare cases of serotonin syndrome<em>, </em>convulsion, and coma), the gastrointestinal system (nausea/vomiting), and the cardiovascular system (hypotension<em>, </em>tachycardia, QT interval prolongation, and arrhythmia) and electrolyte/fluid balance conditions (hypokalaemia, hyponatraemia).</p><p><u>Management</u></p><p>There is no specific antidote. Establish and maintain an airway, ensure adequate oxygenation and respiratory function. Gastric lavage and the use of activated charcoal should be considered. Gastric lavage should be carried out as soon as possible after oral ingestion. Cardiac and vital signs monitoring are recommended along with general symptomatic supportive measures.</p><p>ECG monitoring is advised in case of overdose in patients with congestive heart failure/bradyarrhythmias, in patients using concomitant medications that prolong the QT interval, or in patients with altered metabolism, e.g. liver impairment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antidepressants, selective serotonin reuptake inhibitors ATC-code: N06AB10</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Escitalopram is a selective inhibitor of serotonin (5-HT) re-uptake with high affinity for the primary binding site. It also binds to an allosteric site on the serotonin transporter, with a 1000 fold lower affinity.</p><p>&nbsp;</p><p>Escitalopram has no or low affinity&nbsp; for a number of receptors including 5-HT<sub>1A</sub>, 5-HT<sub>2</sub>, DA D<sub>1</sub>&nbsp;&nbsp;&nbsp;&nbsp; and D<sub>2</sub> receptors, <em>a</em><sub>1</sub>-, <em>a</em><sub>2</sub>-, <em>B</em>-adrenoceptors, histamine H<sub>1</sub>, muscarine cholinergic, benzodiazepine,&nbsp; and opioid receptors.</p><p>&nbsp;</p><p>The inhibition of 5-HT re-uptake is the only likely mechanism of action explaining the pharmacological and clinical effects of escitalopram.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>In a double-blind, placebo-controlled ECG study in healthy subjects, the change from baseline in QTc (Fridericia-correction) was 4.3 ms (90% CI: 2.2, 6.4) at the 10 mg/day dose and 10.7 ms</p><p>(90% CI: 8.6, 12.8) at the supratherapeutic dose 30 mg/day (see sections 4.3, 4.4, 4.5, 4.8 and 4.9).</p><p><u>Clinical efficacy</u></p><p>Major depressive episodes</p><p>Escitalopram has been found to be effective in the acute treatment of major depressive episodes in three out of four double-blind, placebo controlled short-term (8-week) studies. In a long-term relapse prevention study, 274 patients who had responded during an initial 8-week open label treatment phase with Escitalopram 10 or 20 mg/day, were randomised to continuation with Escitalopram at the same dose, or to placebo, for up to 36 weeks. In this study, patients receiving continued Escitalopram experienced a significantly longer time to relapse over the subsequent 36 weeks compared to those receiving placebo.</p><p>Social anxiety disorder</p><p>Escitalopram was effective in both three short-term (12- week) studies and in responders in a 6- month relapse prevention study in social anxiety disorder. In a 24-week dose-finding study, efficacy of 5, 10 and 20 mg Escitalopram has been demonstrated.</p><p>Generalised anxiety disorder</p><p>Escitalopram in doses of 10 and 20 mg/day was effective in four out of four placebo-controlled studies.</p><p>In pooled data from three studies with similar design comprising 421 Escitalopram-treated patients and 419 placebo-treated patients there were 47.5% and 28.9% responders respectively and 37.1% and 20.8% remitters. Sustained effect was seen from week 1.</p><p>Maintenance of efficacy of Escitalopram 20mg/day was demonstrated in a 24 to 76 week, randomised, maintenance of efficacy study in 373 patients who had responded during the initial 12-week open-label treatment.</p><p>Obsessive-compulsive disorder</p><p>In a randomised, double-blind, clinical study, 20 mg/day Escitalopram separated from placebo on the Y-BOCS total score after 12 weeks. After 24 weeks, both 10 and 20 mg/day Escitalopram were superior as compared to placebo.<br />Prevention of relapse was demonstrated for 10 and 20 mg/day Escitalopram in patients who responded to escitalopram in a 16-week open-label period and who entered a 24-week, randomised, double-blind, placebo controlled period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; <u>Absorption</u></p><p>Absorption is almost complete and independent of food intake. (Mean time to maximum concentration (mean T<sub>max</sub>) is 4 hours after multiple dosing).</p><p>As with racemic citalopram, the absolute bioavailability of Escitalopram is expected to be about 80%.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The apparent volume of distribution (V<sub>d,<em>B</em></sub>/F) after oral administration is about 12 to 26 L/kg. The plasma protein binding is below 80% for escitalopram and its main metabolites.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Escitalopram is metabolised in the liver to the demethylated and didemethylated metabolites. Both of these are pharmacologically active. Alternatively, the nitrogen may be oxidised to form the N- oxide metabolite. Both parent substance and metabolites are partly excreted as glucuronides. After multiple dosing the mean concentrations of the demethyl and didemethyl metabolites are usually 28-31% and &lt;5%, respectively, of the Escitalopram concentration. Biotransformation of Escitalopram to the demethylated metabolite is mediated primarily by CYP2C19. Some contribution by the enzymes CYP3A4 and CYP2D6 is possible.</p><p><u>Elimination</u></p><p>The elimination half-life (t&frac12;<em><sub>B</sub></em>) after multiple dosing is about 30 hours and the oral plasma clearance (Cl<sub>oral</sub>) is about 0.6 L/min. The major metabolites have a significantly longer half-life. Escitalopram and major metabolites are assumed to be eliminated by both the hepatic (metabolic) and the renal routes, with the major part of the dose excreted as metabolites in the urine.</p><p><u>Linearity</u></p><p>There is linear pharmacokinetics. Steady-state plasma levels are achieved in about 1 week. Average steady-state concentrations of 50 nmol/L (range 20 to 125 nmol/L) are achieved at a daily dose of 10 mg.</p><p><u>Elderly patients (&gt; 65 years)</u></p><p>Escitalopram appears to be eliminated more slowly in elderly patients compared to younger patients. Systemic exposure (AUC) is about 50 % higher in elderly compared to young healthy volunteers.</p><p><u>Reduced hepatic function</u></p><p>In patients with mild or moderate hepatic impairment (Child-Pugh Criteria A and B), the half-life of Escitalopram was about twice as long and the exposure was about 60% higher than in subjects with normal liver function.</p><p><u>Reduced renal function</u></p><p>With racemic citalopram, a longer half-life and a minor increase in exposure have been observed in patients with reduced kidney function (CL<sub>cr</sub> 10-53 ml/min). Plasma concentrations of the metabolites have not been studied, but they may be elevated.</p><p><u>Polymorphism</u></p><p>It has been observed that poor metabolisers with respect to CYP2C19 have twice as high a plasma concentration of Escitalopram as extensive metabolisers. No significant change in exposure was observed in poor metabolisers with respect to CYP2D6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No complete conventional battery of preclinical studies was performed with Escitalopram since the bridging toxicokinetic and toxicological studies conducted in rats with Escitalopram and citalopram showed a similar profile. Therefore, all the citalopram information can be extrapolated to Escitalopram.</p><p>In comparative toxicological studies in rats, Escitalopram and citalopram caused cardiac toxicity, including congestive heart failure, after treatment for some weeks, when using dosages that caused general toxicity. The cardiotoxicity seemed to correlate with peak plasma concentrations rather than to systemic exposures (AUC). Peak plasma concentrations at no-effect-level were in excess (8-fold) of those achieved in clinical use, while AUC for Escitalopram was only 3- to 4-fold higher than the exposure achieved in clinical use. For citalopram AUC values for the S-enantiomer were 6- to 7-fold higher than exposure achieved in clinical use. The findings are probably related to an exaggerated influence on biogenic amines i.e. secondary to the primary pharmacological effects, resulting in haemodynamic effects (reduction in coronary flow) and ischaemia. However, the exact mechanism of cardiotoxicity in rats is not clear. Clinical experience with citalopram, and the clinical trial experience with Escitalopram, do not indicate that these findings have a clinical correlate.</p><p>Increased content of phospholipids has been observed in some tissues e.g. lung, epididymides and liver after treatment for longer periods with Escitalopram and citalopram in rats. Findings in the epididymides and liver were seen at exposures similar to that in man. The effect is reversible after treatment cessation. Accumulation of phospholipids (phospholipidosis) in animals has been observed in connection with many cationic amphiphilic medicines. It is not known if this phenomenon has any significant relevance for man.</p><p>In the developmental toxicity study in the rat embryotoxic effects (reduced foetal weight and reversible delay of ossification) were observed at exposures in terms of AUC in excess of the exposure achieved during clinical use. No increased frequency of malformations was noted. A pre- and postnatal study showed reduced survival during the lactation period at exposures in terms of AUC in excess of the exposure achieved during clinical use.</p><p>Animal data have shown that citalopram induces a reduction of fertility index and pregnancy index, reduction in implantation number and abnormal sperm at exposure well in excess of human exposure. No animal data related to this aspect are available for Escitalopram.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Core tablet content:</u></p><p>Microcrystalline cellulose, Talc, Colloidal silicon dioxide, Croscarmellose sodium and Magnesium Stearate.</p><p><u>Coating content:</u></p><p>Opadry white (which contains, Hypromellose, Titanium dioxide, Propylene glycol and Talc).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Setapro 10 mg Film Coated Tablets are packed as 10 Tablets in Aluminum-PVC/PVDC blister containing 30 (3x10) film coated tablets in outer carton with Patient Information Leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company Limited
Plot No. ME1:3, Phase V, Industrial City, P.O. Box 6267, Jeddah-21442, Kingdom of Saudi Arabia.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May-2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>